Wednesday, July 18, 2018
News
NEWS HOME
»
PRESS RELEASES

Jardiance® reduced risk of cardiovascular death in people with type 2 diabetes and established CV disease* independent of background blood sugar control
  SocialTwist Tell-a-Friend  
   


Date: 13-09-2017 11:17AM
Source: Boehringer Ingelheim
Category: Business/ Finance, Pharmaceutical, General, Science & Research, Healthcare & Biotechnology, Pharmaceutical
Location: Ingelheim, Germany & Indianapolis, United States

Business Wire India

New analyses of the landmark EMPA-REG OUTCOME® trial showed that Jardiance® (empagliflozin) reduced the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular (CV) disease*, independent of blood sugar control at the start of the study.1 A reduction in cardiovascular death was also seen when Jardiance® was added to common first and second-line diabetes medications, such as metformin or sulphonylurea.2,3 These results from post-hoc analyses were presented by Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD) in Lisbon, Portugal.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170912005928/en/

“Now that we have a new option for reducing the risk of cardiovascular death among people with type 2 diabetes, we are striving to better understand if there are differences in how patients can benefit,” said Prof. Silvio Inzucchi, Section of Endocrinology, Yale School of Medicine, New Haven, USA, who presented the data today. “These new analyses of the EMPA-REG OUTCOME® trial showed empagliflozin was effective in reducing the risk of cardiovascular death in patients with type 2 diabetes and established cardiovascular disease, no matter what the blood sugar levels at the start of the study were or if empagliflozin was added to commonly used oral blood sugar lowering treatments.”

In all four blood sugar level groups at study start (HbA1c levels of <7.0%, 7.0% to <8.0%, 8.0% to <9.0% and ≥9.0%), patients receiving Jardiance® demonstrated a reduction in the risk of cardiovascular death compared with placebo. This was consistent with the risk reduction seen in the overall trial population* and seen irrespective of whether blood sugar control was improved following introduction of the study treatment (as measured by a decrease in HbA1c level of ≥ 0.5% at week 12).1

Additional post-hoc analyses showed that when Jardiance® was added to metformin or sulphonylurea, the reduction of cardiovascular death compared to placebo was consistent with the overall trial population*. These analyses also showed the proportion of patients with hypoglycaemic adverse events were similar between the placebo and Jardiance® groups in the EMPA-REG OUTCOME® trial.2,3

The 7,020-patient EMPA-REG OUTCOME® trial results, first published in the New England Journal of Medicine in 2015, had shown that Jardiance® reduced the relative risk of cardiovascular death by 38 percent compared to placebo in patients with type 2 diabetes and established cardiovascular disease* on top of standard of care (including glucose-lowering agents and cardiovascular drugs). The overall safety profile of Jardiance® was consistent with that of previous clinical trials and current label information.4,5

“Cardiovascular disease is the primary cause of death in people with type 2 diabetes," said David Kendall, M.D., Distinguished Medical Fellow, Lilly Diabetes. “The results presented at EASD provide further evidence of the benefit empagliflozin can provide to patients with different background blood sugar control.”

“The Boehringer Ingelheim and Eli Lilly Diabetes Alliance leads the paradigm shift in the treatment of people with type 2 diabetes”, said Dr Georg van Husen, Corporate Senior Vice President, Head of the Therapeutic Area CardioMetabolism, Boehringer Ingelheim. “The EMPA-REG OUTCOME® trial showed a remarkable reduction in CV death by 38% and the new data indicates that this effect is independent of the blood sugar control."

About Empagliflozin
Empagliflozin (marketed as Jardiance®) is an oral, once daily, highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor approved for use in Europe, the United States and other markets around the world for the treatment of adults with type 2 diabetes.

Inhibition of SGLT2 with empagliflozin in people with type 2 diabetes and high blood sugar levels leads to excretion of excess sugar in the urine. In addition, initiation of empagliflozin increases excretion of salt from the body (i.e. sodium) and reduces the fluid load of the body’s blood vessel system (i.e. intravascular volume). The glucosuria, natriuresis and osmotic diuresis observed with empagliflozin may contribute to the improvement in cardiovascular outcomes.5

Empagliflozin is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

About EMPA-REG OUTCOME®4
EMPA-REG OUTCOME® was a long-term, multicentre, randomised, double-blind, placebo-controlled trial of more than 7,000 people from 42 countries with type 2 diabetes at high risk for cardiovascular events.

The study assessed the effect of empagliflozin (10 mg or 25 mg once daily) added to standard of care compared with placebo added to standard of care. Standard of care was comprised of glucose-lowering agents and cardiovascular drugs (including for blood pressure and cholesterol). The primary endpoint was defined as time to first occurrence of cardiovascular death, non-fatal heart attack or non-fatal stroke.

Over a median of 3.1 years, Jardiance® significantly reduced the risk of CV death, non-fatal heart attack or non-fatal stroke by 14 percent versus placebo. The risk of CV death was reduced by 38 percent, with no significant difference in the risk of non-fatal heart attack or non-fatal stroke. The overall safety profile of empagliflozin was consistent with that of previous trials.

Intended audiences
This press release is issued from Boehringer Ingelheim Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where Boehringer Ingelheim and Eli Lilly and Company do business.

This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Jardiance and its safety profile, and reflects Lilly's current belief.However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that Jardiance will receive additional regulatory approvals. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Please click on the link below for ‘Notes to Editors’ and ‘References’: http://www.boehringer-ingelheim.com/EASD-2017

*Adult patients with type 2 diabetes and coronary artery disease, peripheral artery disease, or a history of myocardial infarction or stroke


MULTIMEDIA AVAILABLE :
http://www.businesswire.com/news/home/20170912005928/en/


CONTACTS :

Boehringer Ingelheim
Dr Petra Kienle
Product Communication Manager
Email: press@boehringer-ingelheim.com
Phone: +49 (6132) 77 143877
or
Lilly Diabetes
Molly McCully
Communications
Email: mccully_molly@lilly.com
Phone: +1 (317) 478 5423

More Press Releases

Department for International Trade: Life Sciences at the Heart of UK Economy

AveriSource Announces the Appointment of Richard Cronheim as President

Ambuja Cement Leads Skill India Mission in Rajasthan

Universal Laser Systems Expands Its Materials Database with 3M, Victrex and Dexmet Materials

MetLife Foundation Provides More Than One-Quarter Million U.S. Dollars to Fund Entrepreneurs

Make Life a Ride: The All-New BMW G 310 R and the All-New BMW G 310 GS Launched in India

Weizmann Forex Bags Airport Counters Across Five Cities in India

Forevermark Brings in 100 Reasons to Sparkle in the City of Bangalore

AirAsia Celebrates a Decade of World's Best Low-Cost Airline

Tejas Implements 100G DWDM Network for MCM Telecom in Mexico

Ride On and On and On: ‘Three Years, Unlimited Kilometres’ Warranty Now Offered as Standard Across the Entire Range of BMW Motorrad Motorcycles

JPMorgan Chase Bank announces the placement of cash-settled exchangeable bonds into Ping An Insurance (Group) Company of China Limited due 2020

Frost & Sullivan Recognizes Cisco for Its Cyber Security Capabilities and Customer Experience Solutions at the 2018 India ICT Awards

APO Adopts Strategic Foresight-Based Approach to Make Member Countries Future-Ready

Nikhil Ramesh Bags INR 25 Lakhs in the the Spartan Poker’s IOPC Millionaire Tournament

Boston Capital Announces Closing of Boston Capital Income & Value U.S. Apartment Fund

JPMorgan Chase Bank launches offering of cash-settled exchangeable bonds into Ping An Insurance (Group) Company of China Limited due 2020

Hyundai Brilliant Moments – Emotional Recalling Digital Campaign Records More Than '100 Million' Views in Just 17 Days

Technavio Semiconductor Market in East Asia 2017-2021 Report | High Demand for Consumer Electronics to Boost Growth

Lenovo Leaps Forward with Next-Generation ThinkAgile Composable Cloud Platform

Presenting an All New Menu and Appointment of Chef Abdul Quddus at Saffron, the Indian Specialty Restaurant at JW Marriott Mumbai Juhu

22nd Century Announces the Immediate Feasibility of the FDA’s Nicotine Reduction Plan

CMAI’s 67th National Garment Fair to Continue up to 19th July 2018

More Than Half of Sub-Saharan Africa to Be Connected to Mobile by 2025, Finds New GSMA Study

Cushman & Wakefield To Acquire Its Irish Affiliate From Sherry FitzGerald Group

NEC and dotData Use AI to Accelerate Data Science for the SMBC Group

GSMA Finds That Consumers in Developing Countries Are Hard Hit by High Spectrum Prices

Rocheston Launches Professional Certification Programmes With Test Delivery Partner Pearson VUE

Azure Power's Portfolio Surpasses 3 Gigawatts

New SAS® Customer Intelligence Offering Accelerates, Automates and Streamlines Marketing Planning Activities

Merck Foundation Concludes Their First Merck Health Media Training to Break the Stigma Around Infertility in Africa

Rakhibazaar.com - Making Raksha Bandhan Memorable with Massive Rakhi Collection 2018

House of Hiranandani Bags Two Prestigious Real Estate Awards

The Countdown Begins to the One of Biggest Outbound- MICE & Luxury Travel Platform

Fischer & Schickendantz and Solution Alliance SRL Adopt Andersen Brand in Uruguay

Is India Ready for August 4 Trade Scrimmage, Asks the Forum of Indian Food Importers

Pidilite Strengthens Its International Presence; Unveils a State-of-the-Art Adhesive Manufacturing Plant in Srilanka

BMW India Extends Special Service Support for Flood-affected Customers in Mumbai

Bank of America Reports Second-Quarter 2018 Financial Results

 
TRENDING TOPICS
 
 
 
CITY NEWS
MORE CITIES
INDIA WORLD ASIA
NDA Govt has failed on all fronts, huge ...
Amarinder writes to Kumaraswamy for prem...
Capt Amarinder writes to Rajnath for nat...
Sukhbir asks partymen to oppose Cong gov...
SC stays bail of accused in drug cases: ...
IAS, HCS officers in Haryana directed to...
More...    
 
 Top Stories
Gujarat exports rise to Rs 660 bill... 
Work commences on another version o... 
Incessant downpour continues in Sau... 
Boeing, Vistara confirm agreement f... 
Assamese and Malwi folk music perfo... 
Come clean on reservation for Dhang... 
PDP owes its emergence to avowed ... 
Amarnath yatra: 7,351 pilgrims pay ...